Atlas-backed Dyne taps Joshua Brumm as CEO; Sekar Kathiresan woos cardiologist to gene editing startup
→ Romesh Subramanian’s new biotech startup, Dyne Therapeutics, which is using oligonucleotides to degrade RNA responsible for disease has brought on Joshua Brumm as president and CEO. Subramanian will now take on the CSO role after launching the biotech as entrepreneur-in-residence at Atlas Venture. Brumm makes the leap after a stint as COO and CFO of Kaleido Biosciences, where he led the company’s IPO and helped bring its lead program into Phase II development. Prior to Kaleido, Brumm was the COO and CFO at Versartis. His other previous roles span Pharmacyclics, ZELTIQ Aesthetics, Proteolix, Citigroup Global Markets and Morgan Stanley.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.